TC BioPharm (NASDAQ: TCBP) a clinical-stage biotechnology company developing allogeneic gamma-delta T cell therapies, announced the execution of a non-binding letter of intent to acquire a commercial-stage ophthalmic pharmaceutical company specializing in glaucoma and ocular hypertension treatments. The acquisition target has an FDA-approved once-daily eye drop and a pipeline of ophthalmology assets, with a commercial launch expected to drive revenue growth in 2025. TC BioPharm plans to finalize a binding agreement in the coming weeks and complete the all-stock transaction in the third quarter of 2025, expanding its portfolio into new therapeutic areas.ย ย
To view the full press release, visit: https://ibn.fm/nbejyย
About TC BioPharm Holdings PLCย
TC BioPharm is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue. TC BioPharm is the leader in developing gamma-delta T cell therapies, and the first company to conduct phase II/pivotal clinical studies in oncology. The company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line โ Phase 2b/3 pivotal trial for OmnImmune(R) in treatment of acute myeloid leukemia using the companyโs proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide. For more information about the company, visitโฏ www.tcbioparm.com.ย
NOTE TO INVESTORS:โฏThe latest news and updates relating to TCBP are available in the companyโs newsroom at โฏhttps://ibn.fm/TCBPย
About BioMedWire
BioMedWireย (โBMWโ) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within theย Dynamic Brand Portfolioย @ย IBNย that delivers:ย (1) access to a vast network of wire solutions viaย InvestorWireย to efficiently and effectively reach a myriad of target markets, demographics and diverse industries;ย (2) article andย editorial syndication to 5,000+ outlets;ย (3) enhancedย press release enhancementย to ensure maximum impact;ย (4)ย social media distributionย via IBN to millions of social media followers;ย and (5) a full array of tailoredย corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in todayโs market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, โBiotechโ to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visitย https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:ย https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered byย IBN
